Oxford BioMedica PLC

137 articles with Oxford BioMedica PLC

• Oxford Biomedica: Exercise of Subscription Option by Novo Holdings

  5/29/2019

  Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announces that, further to the announcement of 28 May in relation to Novo Holdings’ agreement to subscribe for 6,568,024 new ordinary shares in OXB (the “Subscription Shares”) at a price of £6.90 per share (the “Subscription Price”),

• Oxford Biomedica announces strategic investment by Novo Holdings A/S

  5/28/2019

  Oxford Biomedica plc (LSE:OXB) (“OXB” or “the Group”), a leading gene and cell therapy group, today announces that Novo Holdings A/S (“Novo Holdings”), has agreed to invest up to £53.5 million in the Group in return for new ordinary shares representing up to 10.1% of the outstanding shares after the capital increase (the “Transaction”).

• 

  Artificial Intelligence is Ramping up in Drug Development

  5/7/2019

  AstraZeneca announced a long-term collaboration deal with BenevolentAI, a UK-based company focused on combining computational medicine and advanced artificial intelligence.This deal only marks one of the most recent AI team-ups announced in the biopharma industry.

• Oxford Biomedica notes that Axovant has announced the dosing of the first patient in the second cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD

  4/30/2019

  Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, notes that Axovant Gene Therapies Ltd. (NASDAQ: AXGT) has announced the dosing of the first patient of the second cohort in the SUNRISE-PD Phase 2 trial of AXO-Lenti-PD in Parkinson’s disease patients.

• Oxford Biomedica to present at the Annual Meeting of the American Society of Gene & Cell Therapy

  4/30/2019

  Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announced that data from five studies will be highlighted in two oral presentations and three poster sessions at the American Society of Gene & Cell Therapy 22nd Annual Meeting, taking place between 29 April and 2 May in Washington, DC, USA.

• Oxford Biomedica notes the Japanese approval of Kymriah® (tisagenlecleucel), the first CAR-T cell therapy authorised in Asia

  3/26/2019

  Approved for the treatment of two distinct indications – CD19-positive relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) and CD19-positive r/r diffuse large B-cell lymphoma (DLBCL).

• 

  BioForest Hotbed: The Fastest-Growing Life Science Market

  3/14/2019

  A recent report by the U.S. Bureau of Labor Statistics and CBRE Research identified Seattle—which happens to be the BioSpace Bio Forest Hotbed—as the fastest-growing life science market in the top 10 from 2014 to 2017, with a greater than 17-percent growth.
• 

  Oxford Biomedica Teams With Microsoft to Use AI to Improve Gene Therapies

  3/13/2019

  The goal is to improve the yield and quality of next-generation gene therapy vectors—typically viruses—using artificial intelligence (AI) and machine learning.

• Oxford Biomedica announces R&D collaboration with Microsoft to improve gene and cell therapy manufacturing using the intelligent cloud and machine learning

  3/12/2019

  Cell and gene therapy has the potential to transform medicine, providing long-term and potentially curative treatment options for a wide range of diseases.

• Oxford Biomedica notes Axovant's update on Phase 2 trial of AXO-Lenti-PD gene therapy in Parkinson’s disease

  3/11/2019

  Axovant reported 3-month data from the first dose cohort in the open-label, dose-escalation portion of the ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD for the treatment of Parkinson’s disease.

• Kymriah® (tisagenlecleucel, formerly CTL019) receives European Commission Approval

  8/28/2018

  Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes that the European Commission (EC) has approved the Novartis CAR-T cell therapy, Kymriah® (tisagenlecleucel, formerly CTL019).

• 

  Axovant Licenses Gene Therapy for Parkinson’s Disease from Oxford BioMedica

  6/6/2018

  Axovant Sciences, one of Vivek Ramaswamy’s biotech startups, is taking another shot, this time at Parkinson’s disease.

• Oxford BioMedica and Axovant Sciences enter into a $842.5 Million Exclusive Worldwide Licence Agreement for OXB-102 for the Treatment of Parkinson’s Disease

  6/6/2018

  ~ Conference call for analysts to be held at 2:30pm BST / 9:30am ET (see details below)

• 

  Oxford BioMedica Wins $105M Gene Therapy Contract From Bioverativ

  2/15/2018

  The deal includes a licence to use OXB's LentiVector Enabled technology and access to its industrial-scale manufacturing technology.

• Oxford BioMedica Announces A £2 Million Two-Year Collaboration Co-Funded By Innovate UK

  8/14/2017

• Oxford BioMedica Forges A $100 Million+ CAR-T Supply Deal With Novartis AG

  7/7/2017

• Oxford BioMedica PLC Notes Findings On CTL019 From Phase II JULIET Study Presented At The 14th Meeting Of International Conference On Malignant Lymphoma (ICML)

  6/15/2017

• Orchard Therapeutics Announces Strategic Alliance With Oxford BioMedica PLC

  11/29/2016

• Oxford BioMedica PLC Announces Expanded Collaboration And Licence With Immune Design Corporation

  3/7/2016

• Oxford BioMedica PLC Release: Interim Results For The Six Months Ended 30 June 2015

  8/27/2015